Synopsys(SNPS)
Search documents
Synopsys(SNPS) - 2025 Q4 - Annual Results
2025-12-10 21:12
Revenue Performance - Fourth quarter revenue for fiscal year 2025 was $2.255 billion, a 38% increase from $1.636 billion in the same quarter of fiscal year 2024[2] - Full-year revenue for fiscal year 2025 reached $7.054 billion, reflecting a 15% increase from $6.127 billion in fiscal year 2024[2] - Total revenue for the twelve months ended October 31, 2025, increased to $7,054,178, up from $6,127,436 in the previous year, representing a growth of approximately 15.1%[33] - Revenue from the Design Automation segment for the twelve months ended October 31, 2025, was $5,302.4 million, up 25.6% from $4,221.1 million in 2024[44] - The Design IP segment revenue decreased to $1,751.8 million in 2025, down 8.1% from $1,906.3 million in 2024[44] Income and Earnings - Non-GAAP net income for the fourth quarter of fiscal year 2025 was $543.1 million, or $2.90 per diluted share, compared to $529.9 million, or $3.40 per diluted share, in the fourth quarter of fiscal year 2024[6] - GAAP net income for fiscal year 2025 was $1.336 billion, or $8.07 per diluted share, down from $1.442 billion, or $9.25 per diluted share, in fiscal year 2024[5] - Non-GAAP earnings per diluted share for fiscal year 2025 was $12.91, compared to $13.20 in fiscal year 2024[6] - Net income attributed to Synopsys for the twelve months ended October 31, 2025, was $1,332,220, compared to $2,263,380 in the previous year, indicating a decrease of about 41.2%[34] - Net income for the twelve months ended October 31, 2025, was $1,333,251, a decrease of 40.4% compared to $2,235,810 in 2024[40] Backlog and Future Expectations - The company reported a record backlog of $11.4 billion, indicating strong business resilience[3] - The company expects fiscal year 2026 revenue to be approximately $9.610 billion, including $2.9 billion from Ansys[4] - The anticipated impact of divested businesses is approximately $110 million on revenue for fiscal year 2026[4] Expenses and Costs - Research and development expenses for the twelve months ended October 31, 2025, were $2,479,338, an increase from $2,082,360 in the previous year, reflecting a growth of approximately 19.1%[33] - Total current assets decreased to $6,012,102 as of October 31, 2025, from $6,469,666 a year earlier, a decline of about 7.1%[36] - Total liabilities increased to $19,897,446 as of October 31, 2025, compared to $4,050,355 in the previous year, showing a significant rise[36] - The company reported a gross margin of $5,430,629 for the twelve months ended October 31, 2025, compared to $4,882,147 in the previous year, representing an increase of approximately 11.2%[33] Strategic Initiatives - The company plans to integrate Ansys fully and drive operational efficiency in fiscal year 2026[3] - The company plans to reallocate resources in its Design IP segment to focus on higher growth opportunities, indicating a strategic shift[30] - Synopsys expects to realize synergies from the integration of Ansys, which is anticipated to impact future performance positively[30] - The company has planned stock repurchases as part of its capital allocation strategy, reflecting confidence in its financial position[30] Cash Flow and Financing - Cash flows from operating activities increased to $1,518,608 in 2025 from $1,407,029 in 2024, reflecting a growth of 7.9%[40] - Cash, cash equivalents, and restricted cash at the end of the period were $2,893,721, down from $3,898,729 at the beginning of the year, reflecting a decrease of 25.7%[41] - The company reported a net cash used in investing activities of $(15,881,269) in 2025, compared to a net cash provided of $1,223,013 in 2024[40] - Proceeds from debt in financing activities amounted to $14,329,340 in 2025, with a significant increase compared to no proceeds in 2024[40] Operating Margins - Adjusted operating income for the Design Automation segment increased to $2,213.5 million in 2025, a rise of 35.6% from $1,631.9 million in 2024[44] - Total adjusted segment operating income for the twelve months ended October 31, 2025, was $2,632.9 million, compared to $2,362.1 million in 2024, marking an increase of 11.4%[46] - The adjusted operating margin for the Design Automation segment improved to 41.7% in 2025 from 38.7% in 2024[44] Tax and Restructuring - Synopsys will transition to a three-year normalized non-GAAP tax rate starting in fiscal year 2026, enhancing consistency across reporting periods[60] - The projected annual non-GAAP tax rate is influenced by the acquisition of Ansys in Q3 of fiscal year 2025 and the enactment of the One Big Beautiful Bill Act, affecting taxable income from fiscal year 2026[60] - Restructuring activities are initiated to align costs with operating plans, including severance and facility closures, which are not considered part of core operations[58] Core Business Assessment - Gains and losses from the sale of equity investments in privately held companies are excluded from core business assessments[59] - Changes in the fair value of non-qualified deferred compensation plans are not used to assess core profitability[59] Company Overview - Synopsys is a leader in engineering solutions, focusing on silicon design, IP, simulation, and analysis solutions[62] - The company partners with customers across various industries to enhance R&D capabilities and productivity[62]
Synopsys Posts Financial Results for Fourth Quarter and Fiscal Year 2025
Prnewswire· 2025-12-10 21:05
Synopsys headquarters in Sunnyvale, Calif. (PRNewsfoto/Synopsys, Inc.) "The Synopsys team delivered a solid finish to a year that redefined our company as the leader in engineering solutions from silicon to systems," said Sassine Ghazi, president and CEO of Synopsys. "We enter fiscal year 2026 with an intense focus on driving sustainable growth and margin expansion through continued innovation and disciplined execution." "We finished the year with record revenue and strong backlog of $11.4 billion dollars, ...
Nvidia Just Invested $2B in Synopsys—Any Value Here?
247Wallst· 2025-12-10 15:37
Core Viewpoint - Recent dealmaking in the AI sector has intensified concerns regarding an AI bubble, reflecting a growing skepticism among some investors [1] Group 1 - The current wave of dealmaking in the AI industry is characterized as circular, indicating a potential lack of genuine innovation and value creation [1] - The fears surrounding the AI bubble have escalated, suggesting that investors are increasingly wary of overvaluation in the sector [1]
Synopsys upgraded, Warner Bros. downgraded: Wall Street’s top analyst calls
Yahoo Finance· 2025-12-10 14:41
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors need to know, as compiled by The Fly.Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialTop 5 Upgrades: Goldman Sachs upgraded Viking Holdings ( VIK ) to Buy from Neutral with a price target of $78, up from $66. The firm says the company’s “differentiated” geographic exposure and higher-income demog ...
SNPS NOTIFICATION: BFA Law Notifies Synopsys, Inc. Investors of the Pending Class Action Lawsuit and Upcoming December 30 Legal Deadline
Newsfile· 2025-12-10 12:17
SNPS NOTIFICATION: BFA Law Notifies Synopsys, Inc. Investors of the Pending Class Action Lawsuit and Upcoming December 30 Legal DeadlineDecember 10, 2025 7:17 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - December 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Synopsys, Inc. (NASDAQ: SNPS) and certain of the Company's senior executives for securities fraud after a significant stock d ...
Rosenblatt下调新思科技目标价至560美元

Ge Long Hui· 2025-12-10 08:51
Rosenblatt将新思科技的目标价从605美元下调至560美元,评级则从"中性"上调至"买入"。(格隆汇) ...
Synopsys Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga· 2025-12-10 07:05
Group 1 - Synopsys, Inc. is set to release its fourth-quarter earnings results on December 10, with expected earnings of $2.88 per share, a decrease from $3.40 per share in the same period last year [1] - The consensus estimate for Synopsys' quarterly revenue is $2.24 billion, up from $1.64 billion reported in the previous year [1] - On December 1, NVIDIA and Synopsys announced an expansion of their partnership to enhance modern engineering and product development [2] Group 2 - Recent analyst ratings for Synopsys include upgrades from Neutral to Buy by Rosenblatt, with a revised price target of $560 [4] - B of A Securities upgraded Synopsys from Underperform to Neutral, adjusting the price target to $500 [4] - Citigroup initiated coverage with a Buy rating and a price target of $580 [4] - Mizuho maintained an Outperform rating but reduced the price target from $700 to $600 [4] - Stifel maintained a Buy rating while lowering the price target from $650 to $550 [4]
Nintendo shares fall as global memory squeeze raises risks for Switch 2
Invezz· 2025-12-10 07:03
Core Insights - Nintendo's shares have experienced a decline of up to 2.6%, highlighting a broader trend in the tech supply chain related to increasing memory costs affecting gaming hardware [1] Industry Impact - The rising memory costs are causing significant ripples throughout the gaming hardware sector, indicating potential challenges for companies reliant on these components [1]
美银下调新思科技目标价至500美元
Ge Long Hui· 2025-12-10 03:09
美银证券将新思科技的目标价从525美元下调至500美元,评级则从"跑输大市"上调至"中性"。(格隆汇) ...
Holzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against MoonLake Immunotherapeutics (MLTX), DexCom, Inc. (DXCM), and Synopsys, Inc. (SNPS)
Globenewswire· 2025-12-09 16:07
ATLANTA, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC reminds investors of the deadline to seek to be appointed lead plaintiff in the following class action lawsuits: MoonLake Immunotherapeutics (MLTX) The shareholder class action lawsuit filed against MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material facts regarding SLK’s purported superiority to monoclonal antibodi ...